Doctors login

News

Croma-Pharma reveals new packaging design for the Arthrex ACP® double syringe system

(Leobendorf, October 14th 2019) Croma-Pharma GmbH (Croma) is moving forward in harmonizing its aesthetic portfolio, continuously. In the course of the portfolio alignment Croma proudly introduces its own branded packaging design for the Arthrex ACP® double syringe system. The new packaging design integrates to the unique appearance of the Croma product range and consistency with Croma as comprehensive umbrella brand is given. Since April 2017 Croma-Pharma GmbH and Arthrex GmbH operate a successful cooperation with the personalized cell therapy device Arthrex ACP® as part of Croma’s product family. The Arthrex ACP® double syringe system for aesthetic applications is exclusively distributed in 9 European countries by Croma.

About Arthrex ACP®

The Arthrex ACP® double syringe system builds the basis of the Arthrex personalized cell therapy. It enables closed, rapid, and simple production of platelet rich plasma (PRP) which harnesses the body’s own healing and regeneration processes. PRP’s medicinal effect originates from a multitude of growth factors and signalling molecules found in platelets and plasma. No synthetic separation gels or anticoagulants are used as the PRP is separated from the other blood components in a purely physical process. The innovative Arthrex ACP® double syringe allows simple preparation of clinically evaluated and proven PRP without having to compromise on safety and quality. 

About Arthrex GmbH

As Croma is always committed to high quality standards, and Arthrex is renowned for its high quality products, support and reliability the cooperation was the consequent implication. With products such as the Arthrex ACP® double syringe, Arthrex is one of the world’s leading companies in the field of biotechnology, since 1981. The Arthrex ACP® double syringe has been a success story since 2007. Millions of Arthrex ACP®double syringes have already been used by physicians all over the world.

Croma-Pharma GmbH establishes affiliate in UK

Croma-Pharma has now terminated the cooperation with its former distributor Schuco by mutual agreement to build up its own sales structure.

Starting in September 2019, Croma will establish its own London-based affiliate to market its product portfolio in the field of minimally invasive aesthetic medicine in the UK. The cooperation with the previous distributor Schuco was terminated by mutual agreement. Croma is pleased to welcome Julian Popple as its new UK Country Manager who has launched a range of pharmaceutical and aesthetics products for large pharmaceutical companies in the UK, Germany and Italy. Together with his team, he will position and distribute Croma´s aesthetic portfolio. Besides the HA Filler from the own production site as the main product, Croma markets PDO lifting threads, a Platelet Rich Plasma (PRP) system in cooperation with Arthrex and the personalised skincare UniverskinTM in the UK. “Croma aims to provide the best product quality to its customers, while also supporting them to grow their business. An own affiliate office in the UK enables a much closer cooperation and stronger working relationship with our customers”, emphasises managing director Andreas Prinz. Furthermore, Croma will launch its new branded HA Filler saypha® at the CCR from 10 - 11/10/2019 on the UK market.

Croma-Pharma donates for blind people in Africa

The Lower Austrian pharmaceutical company Croma-Pharma supports the charitable organization Licht für die Welt by donating medical products (viscoelastics).

Last week, Croma-Pharma, represented by Martin Schöller (Managing Director), again presented a generous donation of medical products (viscoelastics) for the operation on cataracts to Licht für die Welt.

For 18 years, Croma-Pharma supports the organization's work with generous product donations that enables hundreds of thousands of eye surgeries. "Croma stands for the right of people in poverty areas to provide quality medical care. Therefore, we have been supporting the work of Licht für die Welt for many years pleased to be able to make a contribution to sustainably improving the quality of life of these people, "emphasized Martin Schöller. 

Cataract is still the leading cause of blindness in the world. This operation costs on average only 30 euros and takes about 15 minutes. A brief moment, however, which gives the affected people their eyesight for a lifetime.

Jung v. Matt/ Donau & Croma won CCA-Venus-Award in Bronze

The aesthetic pictures of the brand campaign could convince in the category photography.

This year Croma Pharma and the agency Jung von Matt/Donau won the bronze Venus Award in the field of photography with the subjects of the brand campaign.
The most important creative price of Austria honors the best ideas of the communication industry for the market place Austria and places their creators as well as their clients into the spotlight.

Fotocredit CCA/H.Plein/P.Lichtenegger

Croma-Pharma completes rebranding of its HA filler range

On January 02nd, Croma-Pharma GmbH (Croma) has stated that the company is moving forward in its plan harmonizing the different brands of its aesthetic product portfolio.

 The previous HA filler brand “Princess®” is replaced by the brand “saypha®” in a gradual process throughout international markets, focusing on Europe in the first place.

First and foremost the rebranding became necessary due to Croma’s ongoing globalisation process on the one hand and the advancing approval procedures of  Hugel’s botulinum toxin product Botulax on the other hand, requiring a more medical HA filler brand, exclusively addressing medical professionals. Croma has licensed the product Botulax from the Korean toxin producer Hugel Inc. for Europe and recently established a joint venture company with Hugel, Inc., in order to develop and commercialize Croma’s HA filler and PDO thread products together with Hugel’s product Botulax in the US, Canada, Australia and New Zealand.

Croma’s Managing Director, Andreas Prinz, further explained, “By replacing Princess® with saypha® we actually pursue several different purposes. Primarily, Princess® is not a suitable and approvable brand for all our current and future markets. Furthermore the saypha® brand is consistent with Croma as the all-encompassing umbrella brand, introduced in 2017, under which every product can be streamlined and marketed with a unifying look and feel around the globe. 
In the course of our progressing internationalization process this standardized appearance of the company towards our primary target audience, the medical professionals, becomes absolutely essential. Apart from that, all saypha® products are easy to distinguish from each other which was a customers’ request that we are happy to follow herewith. The saypha® brand also reflects medical science and evidence based medicine, values that Croma felt committed to at any time. In short, by introducing saypha® we are creating a strong global HA filler brand that stands for comprehensive quality, reliability and medical effectiveness.”

 

About saypha®

The Croma HA filler range consists of six products: saypha® RICH, saypha® FILLER (with/without lidocaine), saypha® VOLUME (with/without lidocaine) and saypha® VOLUME PLUS Lidocaine.

Innovation Award for Croma-Pharma

Croma wins German Innovation Award for Lacrimera®

Leobendorf, Juli  2018–As part of the German Innovation Award 2018, Croma received the Winner award for Lacrimera® eye drops in the Medical & Health category. Lacrimera® eye drops are characterised by a multi-patented mode of action that allows a 24-hour ocular surface retention time and to a sustainable treatment of dry eye symptoms. The protective layer created by Lacrimera® eye drops promotes the regeneration of the corneal surface.The prize, awarded in the "Excellence in Business to Consumer" competition class, distinguishes products and solutions across all sectors, which are differentiated above all by user-centeredness and added value compared to previous solutions.


The German Innovation Award is awarded by the German Design Council, which was established by the German Bundestag and endowed by German industry. Only companies nominated by the Expert Committees and Scouts of the German Design Council can participate. The jury is composed of independent, interdisciplinary experts from industry, science, institutions and finance.

Croma is a global player in the dynamically growing segment of minimally invasive aesthetic medicine and a leading European processor of hyaluronic acid. The company sells an annual production of six million hyaluronic acid syringes and its growing aesthetic portfoliothrough a network of own sales organizations, strategic partnerships and distributors in nearly 80 countries. The family-owned company employs more than 350 people worldwide. Production takes place exclusively at the company headquarters in Leobendorf near Vienna, Austria.

 

Contact:

CROMA-PHARMA GmbH
Mag. Stefanie Höhn
Corporate Director Communications
Cromazeile 2
A-2100 Leobendorf
Tel.:     +43 676 846868 190
Mail:    stefanie.hoehn@croma.at
Web: www.croma.at